Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting
March 05 2024 - 4:30PM
Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell
reprogramming company advancing a diverse pipeline of cell
therapies for patients with solid tumors, announced that three
abstracts of new nonclinical data have been accepted for
presentation at the American Association for Cancer Research (AACR)
Annual Meeting 2024 taking place in San Diego, CA, April 5-10.
One oral and two poster presentations will highlight data from
Lyell’s product pipeline and research programs, including:
- An oral presentation on Lyell’s rejuvenation technology which
has shown the potential to turn back the epigenetic clock to
generate more stem-like T cells with reduced epigenetic age and
enhanced proliferation ability
- A poster presentation of nonclinical data on LYL119, Lyell’s
second-generation ROR1-targeted CAR T-cell product candidate
- A poster presentation on technology being advanced through a
collaboration between Lyell and Outpace to enable tumor-restricted
IL-12 activity to enhance solid tumor T cell therapies
Details on the presentations are below.
An oral presentation titled “Rejuvenation of Tumor Infiltrating
Lymphocytes: A novel strategy to revitalize TIL antitumor function
for cell therapy” will highlight Lyell’s rejuvenation technology
which has shown the potential to generate T cells with reduced
epigenetic age, more stem-like properties and enhanced
proliferation ability. Previously published studies have
demonstrated the decline in T-cell function as a person ages. These
new nonclinical data show tumor infiltrating lympyocytes (TIL)
rejuvenated with Lyell’s technology retain a broad T-cell receptor
repertoire and demonstrate sustained proliferation and improved
antitumor activities in vivo.
Presentation details:
- Session Date/Time: Tuesday Apr 9, 2024 2:30 PM - 4:30
PM
- Abstract Number: 6593
- Session Category: Immunology
- Session Title: New Insights for Therapies Modulating
Antitumor T-Cell Responses
New nonclinical data on LYL119, Lyell’s second-generation
ROR1-targeted CAR T-cell therapy, will be presented in a poster
titled “LYL119, a Preclinical ROR1-Targeted CAR T-Cell Product
Incorporating Four Novel Reprogramming Technologies Designed for
Effective Cell Therapy for Solid Tumors.” LYL119 incorporates four
of Lyell’s complementary, stackable T-cell reprogramming
technologies and is designed to create potent ROR1-targeted CAR T
cells with durable function. In this study, LYL119 demonstrated
superior in vivo antitumor efficacy in a mouse xenograft tumor
model across a 10-fold dose range, including at very low cell
doses. In addition, following repeated rounds of tumor cell
killing, LYL119, displayed reduced expression of exhaustion-related
gene signatures and retained unique cell subsets characterized by
upregulation of memory and effector-associated gene signatures.
Presentation details:
- Session Date and Time: Sunday Apr 7, 2024 1:30 PM - 5:00
PM
- Abstract Number: 49
- Session Category: Immunology
- Session Title: Adoptive Cell Therapies 2: CAR-T Cells
A poster presentation titled “Development of Tumor-restricted
IL-12 With Antigen-dependent Expression and Localized IL-12
Activity” highlights an innovative tumor-restricted IL-12
(trIL-12) technology that delivers potent IL-12 stimulation at the
tumor site while avoiding systemic exposure. IL-12 is an
immune-stimulatory cytokine that can induce potent anti-tumor
activity, but unregulated systemic delivery of IL-12 has been shown
to have a limited therapeutic window. trIL-12 was designed
leveraging Outpace’s OUTSMART™ technology to rapidly
auto-inactivate IL-12 after inducible secretion from engineered T
cells with the aim of achieving safe, local delivery of IL-12
activity in the tumor microenvironment. trIL-12 is being advanced
under a collaboration between Lyell and Outpace with the goal of
improving efficacy for T-cell therapies by harnessing the
therapeutic potential of IL-12.
Presentation details:
- Session Date and Time: Tuesday Apr 9, 2024 9:00 AM - 12:30
PM
- Abstract Number: 4067
- Session Category: Immunology
- Session Title: Immune Modulation with Cytokines
About Lyell Immunopharma, Inc.
Lyell is a clinical-stage T-cell reprogramming company advancing
a diverse pipeline of cell therapies for patients with solid
tumors. Lyell is currently enrolling a Phase 1 clinical trial
evaluating a ROR1-targeted CAR T-cell therapy in patients with
relapsed refractory triple-negative breast cancer (TNBC) and
non-small cell lung cancer (NSCLC) and a second Phase 1 clinical
trial evaluating reprogrammed tumor infiltrating lymphocytes (TIL)
in patients with advanced melanoma, NSCLC and colorectal cancer.
The technologies powering its product candidates are designed to
address barriers that limit consistent and long-lasting responses
to cell therapy for solid tumors: T-cell exhaustion and lack of
durable stemness, which includes the ability to persist and
self-renew to drive durable tumor cytotoxicity. Lyell is applying
its proprietary ex vivo genetic and epigenetic reprogramming
technologies to address these barriers in order to develop new
medicines with improved durable clinical outcomes. Lyell is based
in South San Francisco, California with facilities in Seattle and
Bothell, Washington. To learn more, please visit www.lyell.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements expressed or implied in this press
release include, but are not limited to, statements regarding:
Lyell’s anticipated progress, business plans, business strategy and
planned research and clinical trials; the growing pipeline and
potential clinical benefits and therapeutic potential of Lyell’s
product candidates and reprogramming technologies; Lyell’s
collaboration with Outpace Bio and the potential to enable
tumor-restricted IL-12 activity to enhance solid tumor T cell
therapies and improve efficacy for T-cell therapies while
maintaining a favorable safety profile; the potential for Lyell’s
stackable T-cell reprogramming technologies to create potent
ROR1-targeted CAR T cells with durable function; the potential for
Lyell’s rejuvenation technology to turn back the epigenetic clock
to generate more stem-like T cells with reduced epigenetic age and
enhanced proliferation ability; and other statements that are not
historical fact. These statements are based on Lyell’s current
plans, objectives, estimates, expectations and intentions, are not
guarantees of future performance and inherently involve significant
risks and uncertainties. Actual results and the timing of events
could differ materially from those anticipated in such
forward-looking statements as a result of these risks and
uncertainties, which include, but are not limited to, risks and
uncertainties related to: macroeconomic conditions geopolitical
instability; Lyell’s ability to submit planned INDs or initiate and
execute clinical trials on the anticipated timelines, if at all;
Lyell’s limited experience as a company in enrolling and conducting
clinical trials, and lack of experience in completing clinical
trials; potential delays or difficulties in enrolling or retaining
patients in our current and planned clinical trials, including as a
result of any of our competitors obtaining regulatory approval
before us in the same therapeutic areas as our product candidates;
Lyell’s ability to manufacture and supply its product candidates
for its clinical trials; the nonclinical profiles of Lyell’s
product candidates not translating in clinical trials; the
potential for results from clinical trials to differ from
preclinical, early clinical, preliminary or expected results;
significant adverse events, toxicities or other undesirable side
effects associated with Lyell’s product candidates; the significant
uncertainty associated with Lyell’s product candidates ever
receiving any regulatory approvals; Lyell’s ability to obtain or
maintain orphan drug designation for its product candidates or to
take advantage of the benefits associated with such designation;
Lyell’s ability to obtain, maintain or protect intellectual
property rights related to its product candidates; the sufficiency
of Lyell’s capital resources and need for additional capital to
achieve its goals; and other risks, including those described under
the heading “Risk Factors” in Lyell’s Annual Report on Form 10-K
for the year ended December 31, 2023, filed with the Securities and
Exchange Commission (SEC) on February 28, 2024. Forward-looking
statements contained in this press release are made as of this
date, and Lyell undertakes no duty to update such information
except as required under applicable law.
Contact:
Ellen RoseSenior Vice President, Communications and Investor
Relationserose@lyell.com
Lyell Immunopharma (NASDAQ:LYEL)
Historical Stock Chart
From Apr 2024 to May 2024
Lyell Immunopharma (NASDAQ:LYEL)
Historical Stock Chart
From May 2023 to May 2024